This is the authors' abstract. We don't add key points for this paper.
Subjects receiving romyelocel-L showed a decreased incidence of infections, antimicrobial use, and hospitalization, suggesting that romyelocel-L may provide a new option to reduce infections in patients with AML undergoing induction therapy.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Desai et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: